2008: SLE: Clinical Aspects II
Search or Browse by Day

SLE: Clinical Aspects II

Monday, October 27, 2008
1054
Urine Osteoprotegrin (OPG) and Monocyte Chemoattractant Protein-1 (MCP-1) in Lupus Nephritis (LN)
1055
Systemic Lupus Erythematosus Disease Activity: Effect of Peritoneal Dialysis versus Hemodialysis
1056
Control of Blood Pressure Benefits Proteinuria in SLE
1057
Combination Therapy of Mycophenolate Mofetil and FK506 in Lupus Nephritis
1058
Mycophenolate Mofetil for Lupus Nephritis: Reduction in Dose After Complete Response
1059
Bimodal Pattern of Mortality in SLE in African-Americans versus Caucasians
1060
IgM Anti-Beta2 Glycoprotein I is Protective Against Lupus Nephritis and Renal Damage in SLE
1061
Changes in Frequency of Non-Renal ACR Classification Criteria
1062
Autoantibodies in Systemic Lupus Erythematosus (SLE): Comparison of Historical and Concurrent Assessment of Seropositivity
1063
The Role of NGAL as a Biomarker for Lupus Nephritis Flares
1064
Renal Biopsy In Lupus Patients With Low Levels Of Proteinuria
1065
Long-term Safety Profile of Belimumab (Fully Human Monoclonal Antibody to BLyS) in Patients with Systemic Lupus Erythematosus (SLE)
1066
Mycophenolate Mofetil Confers Survival Benefit And Is Safer Than Cyclophosphamide In The Treatment Of Proliferative Lupus Nephritis: A Comprehensive Meta-analysis of 445 Patients In 8 Controlled Trials
1067
Lupus Nephritis Patients Treated With Rituximab Display Reductions In Both Anti-DNA And ENA Autoantibodies That Parallel Clinical Responses
1068
Safety Aspects and Long Term Efficacy of TNF Blockade with Infliximab in Patients with Systemic Lupus Erythematosus
1069
Mycophenolate Mofetil (MMF) for Treatment of Arthritis in Patients with Systemic Lupus Erythematosus (SLE)
1070
Serum And Urinary IL-18 Levels Are Associated With Activity Of SLE And Lupus Nephritis
1071
Urinary MCP-1 And sVCAM-1, And Urine And Serum sTNFR-1 Correlate With Activity Of Lupus Nephritis
1072
Phase 1a Single- and Phase 1b Multiple-Dose Studies of AMG 623 (an anti-BAFF peptibody) in Systemic Lupus Erythematosus (SLE)
1073
Mycophenolate Mofetil Versus Tacrolimus For Active Lupus Nephritis: An Extended Observation Of A Randomized Controlled Trial
1074
Cumulative Incidence And Predictive Factors For Work Disability In Patients With Systemic Lupus Erythematosus (SLE)
1075
A Retrospective Seven-year Analysis Of The Use Of B-cell Depletion Therapy In Systemic Lupus Erythematosus At University College London Hospital: The First Fifty Patients
1076
The Relationship between Renal Activity and Quality of Life in Systemic Lupus Erythematosus
1077
Dose Dependent Reduction in Anti-dsDNA Antibody Levels Observed With Abetimus Sodium Through 52 Weeks in the Phase 3 ASPEN Study (Abetimus Sodium in Patients With a History of Lupus Nephritis)
1078
Effect On Interferon-inducible Gene Expression Signature By ABR-215757, A New Drug In Development For SLE
1079
TNF-like Weak Inducer Of Apoptosis (TWEAK) As A Novel Urinary Biomarker For The Diagnosis Of Lupus Nephritis
1080
Effects Of Chronic Selective BAFF Blockade On Human B Cells In SLE
1081
Different Mechanisms are Involved in Different Organ Manifestation in SLE: Learning from Treatments with Rituximab (anti-CD20) Therapy
1082
Early anti-ribosomal P antibodies commonly target non-C-terminus epitopes before diagnosis
1083
Direct Medical Cost of Renal Flare in Lupus Nephritis
1084
Changes in Quality of Life in the first 5 years of disease in a multicentre cohort of patients with Systemic Lupus Erythematosus (SLE)
1085
The Effect of Socioeconomic Status on Manifestations of SLE
1086
Meaningful Improvements in Health-Related Quality of Life (HRQoL) with Epratuzumab (anti-CD22 mAb Targeting B-cells) in Patients (Pts) with SLE with High Disease Activity: Results from 2 Randomized Controlled Trials (RCTs)
1087
Clinically Meaningful Improvements with Epratuzumab (Anti-CD22 mAb Targeting B-cells) in Patients (Pts) with Moderate/Severe SLE Flares: Results from 2 Randomized Controlled Trials
1088
Epratuzumab (anti-CD22 mAb Targeting B-cells) Provides Clinically Meaningful Reductions in Corticosteroid (CS) Use with a Favorable Safety Profile in Patients with Moderate/Severe Flaring SLE: Results from Randomized Controlled Trials (RCTs)
1089
Serum Free Light Chains as a Biomarker in Systemic Lupus Erythematosus
1090
Increased Concentration of Plasma Pentraxin 3 Levels in Patients with Systemic Lupus Erythematosus: Relationship to Disease Activity
1091
Antibody and Cell-mediated Responses to Influenza Vaccination in Patients with Systemic Lupus Erythematosus and Healthy Controls
1092
The levels of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Pentraxin 3 (PTX3) in Febrile Patients with Systemic Lupus Erythematosus
1093
Zip Code Based Annual Household Income is a Better Socioeconomic Surrogate than Education in Systemic Lupus Erythematosus
1094
Belimumab (Fully Human Monoclonal Antibody to BLyS) Improved or Stabilized Systemic Lupus Erythematosus (SLE) Disease Activity Over 3 Years of Therapy
1256
Cognitive Function Over Time in SLE: The Brain CONECTIONS Inception Cohort
1257
Paired Analysis of Autoantibodies, Cytokines and Chemokines in Cerebrospinal Fluid (CSF) of SLE Patients with Central Neuropsychiatric Manifestations (cNPSLE) With and Without Associated Factors
1258
Fatigue and Oxidative Stress in SLE
1259
Progressive Multifocal Leukoencephalopathy - A National Estimate of Frequency in SLE and Other Rheumatic Diseases
1260
Impact Of Neuropsychiatric Events On Health-Related Quality Of Life Over Seven Years In Patients With Systemic Lupus Erythematosus (SLE)
1261
Michigan Lupus Epidemiology & Surveillance (MILES) Program: Neurologic involvement among SLE patients in a population-based registry
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>